Tag
Long-term data from the ULTIMATE open-label extension study demonstrates sustained efficacy and safety of ublituximab in relapsing multiple sclerosis over five years, with significant reductions in relapse rates and disability progression c
The Phase 2b PARADIGM trial demonstrates that PrimeC—a novel combination of celecoxib and ciprofloxacin—is safe and significantly slows functional decline in ALS patients over 18 months, offering new hope for multi-target neuroprotective st
This phase 2 trial demonstrates that memantine, an NMDA receptor antagonist, significantly reduces premature atrial contractions (PACs) and nonsustained atrial tachycardia burden, suggesting the cardiac glutamatergic system as a novel thera
A large-scale multicenter RCT investigating AI-assisted gastric neoplasm detection found no significant improvement in pathologically confirmed detection rates but demonstrated significant reductions in procedural blind spots and benefits f
The APERITIF trial explored adding low-dose rivaroxaban to standard dual antiplatelet therapy to prevent heart clots after an anterior heart attack. While the addition did not significantly reduce thrombus formation, it did increase minor b
A pivotal randomized clinical trial reveals that targeted training of the ipsilesional arm in chronic stroke patients with severe hemiparesis significantly improves motor speed and hand function, with benefits sustained for six months.
This article examines a Phase 2a trial investigating eslicarbazepine acetate for preventing post-stroke epilepsy. While the primary endpoint was not met due to recruitment challenges, the study provides a critical framework for future antie
The multicenter PREGRALL trial demonstrates that maternal intake of galacto-oligosaccharide/inulin prebiotics from mid-gestation does not reduce the incidence of atopic dermatitis or allergic sensitization in high-risk infants by age one, c
This pilot randomized clinical trial investigated low-dose lithium for Mild Cognitive Impairment (MCI). While primary outcomes regarding cognition and neuroimaging were not statistically significant, the study established the intervention&#
A multicenter randomized trial shows diacerein provides no clinical benefit over placebo for knee pain in patients with MRI-confirmed inflammation, despite its theoretical role as an IL-1β blocker.
A multicentre RCT in England demonstrates that a 10-session brief psychological intervention offers no significant improvement in social functioning or cost-effectiveness for individuals with probable personality disorder, reinforcing the n
Explore how standardized health questionnaires empower children and parents to share their priorities in medical settings, leading to more personalized and effective treatment plans.
The 12-month BOND study found that high-dose benfotiamine (600 mg daily) did not significantly improve corneal nerve fiber length or other neurophysiological markers in patients with type 2 diabetes and symptomatic polyneuropathy, despite s
A multicentre randomized controlled trial demonstrates that robotic telesurgery over distances up to 2800 km is non-inferior to local surgery for urological procedures, maintaining high success rates, low latency, and equivalent safety prof
The ED INNOVATION trial reveals that 7-day extended-release injectable buprenorphine is safe and as effective as sublingual formulations for treatment engagement, offering significant benefits in craving reduction and patient satisfaction e
The Phase 3 LIBERTY-CSU CUPID trials demonstrate that dupilumab significantly reduces itch and hives in patients with chronic spontaneous urticaria uncontrolled by antihistamines, providing a crucial new therapeutic option for those who are
The 5-year follow-up of the LASSO randomized clinical trial demonstrates that while laparoscopic adhesiolysis offers short-term recovery benefits, it provides no significant long-term advantage over open surgery regarding SBO recurrence, in
A multicenter randomized trial of 1,082 extremely preterm infants found that automated FiO2 control did not significantly reduce death or major morbidities compared to manual titration, though it remains a safe labor-saving tool for neonata
This Phase 2 trial of NG101 for gastroparesis did not meet its primary endpoint for nausea severity reduction but showed significant global improvement in patient-reported outcomes and a favorable safety profile, particularly in idiopathic
The CORAL Phase 2b trial demonstrates that oral nalbuphine extended release significantly reduces objective cough frequency and improves patient-reported symptoms in idiopathic pulmonary fibrosis, addressing a critical unmet need for managi
